Role of Egfl7 in Vascular Development and Angiogenesis
Egfl7 在血管发育和血管生成中的作用
基本信息
- 批准号:7625067
- 负责人:
- 金额:$ 40.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgonistAllelesAortaArterial InjuryArteriovenous malformationBindingBiological ModelsBlood IslandBlood VesselsCollagenComplexDefectDevelopmentEGF geneEmbryoEndothelial CellsEndotheliumEphrinsGenesGrowth FactorHumanIn VitroKnock-outLeadLigandsMediatingMusMutationNotch Signaling PathwayPathway interactionsPhasePhenocopyProcessProteinsRepressionResearch PersonnelRoleSignal PathwaySignal TransductionSmall Interfering RNAStagingStem cellsSubfamily lentivirinaeSystemTestingTransforming Growth Factor betaTransgenic MiceVascular Endothelial Growth FactorsVascular SystemVeinsVenousYolk Sacangiogenesisbasecadherin 5chorioallantoic membraneembryonic stem cellgain of functionknock-downloss of functionmembrane modelmutantnotch proteinnoveloverexpressionprogenitorpromoterreceptorvasculogenesis
项目摘要
DESCRIPTION (provided by applicant): Vasculogenesis and angiogenesis are controlled by a complex system of growth factors and their cognate receptors. These include VEGF/VEGFR and angiopoietin/Tie signaling pathways, as well as b-FGF, TGF-beta, ephrins, and their receptors. In addition, the importance of Notch signaling for vascular development and arterial-venous fate specification has been elucidated. While the importance of these pathways for vascular development has been documented, it is likely that other critical factors remain unidentified. Using a "gene trap" approach, we recently identified Egfl7, a novel endothelial-restricted gene that encodes a secreted protein with an EMI domain, two EGF domains, and a putative DSL domain found in Notch ligands. Egfl7 is specifically expressed in the emerging vasculature and its progenitors in the yolk sac blood islands. In adults, Egfl7 is up-regulated during angiogenesis and arterial injury. Our preliminary studies indicate that EGFL7 binds to Notch 1 and 4 in vitro and mediates several of the known Notch effector functions. In the present proposal, we will test the hypothesis that EGFL7 is a novel ligand for Notch, that EGFL7 functions as a Notch agonist, and that EGFL7-induced Notch signaling mediates distinctive and non-redundant processes during vascular development and angiogenesis. We will test these hypotheses in primary human endothelial cells, and by using gain- and loss-of-function approaches in an ES cell in vitro differentiation system and in mice. We are proposing the following aims: Aim 1: Determine the role of EGFL7 in Notch signaling in HUVEC and in a chick chorioallantoic membrane model. Aim 2: Determine whether overexpression of Egfl7 in the endothelium leads to defects in vascular development. We will force expression of Egfl7 in endothelial cells by generating Tie2-Egfl7 transgenic mice, and induce Egfl7 expression in endothelial cells by generating VE-Cadherin:tTA;TRE-Egfl7 transgenic mice. Aim 3: Test whether Egfl7 function is crucial for early stages of vascular development. We will generate mice with a conditional knock-out allele and lentivirus-based siRNA knock-down in ES cells and mouse embryos.
描述(由申请人提供):血管发生和血管生成由生长因子及其同源受体的复杂系统控制。这些包括VEGF/VEGFR和血管生成素/Tie信号传导途径,以及b-FGF、TGF-β、肝配蛋白及其受体。此外,Notch信号传导对血管发育和动脉-静脉命运特化的重要性已被阐明。虽然这些途径对血管发育的重要性已被证明,但其他关键因素可能仍未确定。使用“基因陷阱”的方法,我们最近确定了Egfl 7,一种新的内皮限制性基因,编码分泌蛋白的EMI结构域,两个EGF结构域,和一个假定的DSL结构域中发现的Notch配体。egfl 7在卵黄囊血岛中的新生血管系统及其祖细胞中特异性表达。在成人中,Egfl 7在血管生成和动脉损伤期间上调。我们的初步研究表明,EGFL 7在体外与Notch 1和4结合,并介导几种已知的Notch效应子功能。在本提案中,我们将测试EGFL 7是Notch的新配体,EGFL 7作为Notch激动剂发挥作用,EGFL 7诱导的Notch信号传导介导血管发育和血管生成过程中独特的非冗余过程的假设。我们将在原代人内皮细胞中测试这些假设,并通过在ES细胞体外分化系统和小鼠中使用功能获得和丧失的方法。我们提出以下目标:目标1:确定EGFL 7在HUVEC和鸡绒毛尿囊膜模型中Notch信号传导中的作用。目的2:确定内皮中Egfl 7的过表达是否导致血管发育缺陷。我们将通过产生Tie 2-Egfl 7转基因小鼠来迫使Egfl 7在内皮细胞中表达,并通过产生VE-钙粘蛋白:tTA; TRE-Egfl 7转基因小鼠来诱导Egfl 7在内皮细胞中表达。目的3:测试Egfl 7功能是否对血管发育的早期阶段至关重要。我们将在ES细胞和小鼠胚胎中产生具有条件性敲除等位基因和基于慢病毒的siRNA敲低的小鼠。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Heidi Stuhlmann其他文献
Heidi Stuhlmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Heidi Stuhlmann', 18)}}的其他基金
Training Program in Developmental and Stem Cell Biology
发育和干细胞生物学培训计划
- 批准号:
9260703 - 财政年份:2015
- 资助金额:
$ 40.45万 - 项目类别:
Role of Egfl7 in Angiogenesis and Vascular Injury
Egfl7 在血管生成和血管损伤中的作用
- 批准号:
8448607 - 财政年份:2006
- 资助金额:
$ 40.45万 - 项目类别:
Role of Egfl7 in Angiogenesis and Vascular Injury
Egfl7 在血管生成和血管损伤中的作用
- 批准号:
8297503 - 财政年份:2006
- 资助金额:
$ 40.45万 - 项目类别:
Role of Egfl7 in Vascular Development and Angiogenesis
Egfl7 在血管发育和血管生成中的作用
- 批准号:
7333806 - 财政年份:2006
- 资助金额:
$ 40.45万 - 项目类别:
Role of Egfl7 in Vascular Development and Angiogenesis
Egfl7 在血管发育和血管生成中的作用
- 批准号:
7243496 - 财政年份:2006
- 资助金额:
$ 40.45万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 40.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 40.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 40.45万 - 项目类别: